U.S. Markets close in 3 hrs 38 mins

Synairgen plc (SNG.L)

London Stock Exchange - London Stock Exchange Delayed Price. Currency in GBp
Add to watchlist
8.1250.000 (0.000%)
At close: 4:30PM BST
Full screen
Previous Close8.125
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.000 - 0.000
52 Week Range
Avg. Volume41,358
Market Cap7.42M
PE Ratio (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters4 months ago

    AstraZeneca aims to escape drug sales trough in second half

    AstraZeneca, struggling with loss of patents on blockbusters like cholesterol pill Crestor, reported another quarter of falling drug sales on Thursday as it awaits pivotal clinical trial data that may revive its fortunes. Chief Executive Pascal Soriot believes 2017 will mark the trough for the British group, as it starts to put generic losses behind it and builds up sales of recently launched and experimental cancer medicines. Industry analysts, on average, had forecast revenue of $5.4 billion and earnings of 82 cents, according to Thomson Reuters data.

  • Synairgen Plc :SNG-GB: Earnings Analysis: 2015 By the Numbers
    Capital Cubelast year

    Synairgen Plc :SNG-GB: Earnings Analysis: 2015 By the Numbers

    Click here to see latest analysisSynairgen Plc reports financial results for the year ended December 31, 2015.We analyze the earnings along side the following peers of Synairgen Plc – Sareum Holdings plc and Clinigen Group Plc (SAR-GB and CLIN-GB) that have also reported for this period.HighlightsYear-on-year change in operating cash flow of -203.31% is about […] (Read more...) The post Synairgen Plc :SNG-GB: Earnings Analysis: 2015 By the Numbers appeared first on CapitalCube.

  • We're sorry this is all we were able to find about this topic.